Novo Nordisk A/S Sponsored ADR (NVO)
Why Novo Nordisk stock is rocketing
Novo Nordisk (NYSE: NVO) shares surged in pre-market and after-hours trading after the company secured U.S. regulatory approval for the world's first GLP-1 weight-loss pill, a milestone that materially reshapes the obesity drug market.
Novo Nordisk first out of the gate with oral weight-loss drug, and its stock jumps
Relief rally underway in Novo Nordisk after a difficult year for the stock which saw it lose ground to arch-competitor Eli Lilly.
Novo Nordisk Shares Jump After FDA Approves Pill Version of Wegovy
The approval gives Novo Nordisk a chance to regain ground lost to rival Eli Lilly.
Novo Nordisk up nearly 10% in Frankfurt after US approves weight loss pill
Novo Nordisk's Frankfurt-listed shares opened nearly 10% higher in early trading on Tuesday after the U.S. Food and Drug Administration approved its weight-loss pill.
Novo's Wegovy pill to test demand from consumers with cash
Novo Nordisk's newly approved weight-loss pill version of Wegovy will be a test case for the fast-growing cash-paying consumer market, with plans for the first highly effective oral treatment to go straight to U.S. self-pay channels in early January.
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Dec 2025)
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and over $14 billion in the first nine months of 2025, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO).
Novo Nordisk: Oral Wegovy, Supply Chain, And Restructuring = Big Upside Ahead
Novo Nordisk offers compelling value, trading at a 32% discount to fair value with a 3.6% yield and robust dividend growth. NVO's semaglutide-based drugs drive 74% of sales, but pipeline innovation, capacity expansion, and restructuring support future growth. EPS is projected to dip 2% in 2026 before rebounding 6.8% in 2027, with high single-digit growth anticipated beyond.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Novo Nordisk (NVO) closed at $47.81 in the latest trading session, marking a -2.35% move from the prior day.
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
EU drugs regulator backs higher dose of Novo's Wegovy
Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.
